Condition
mRNA Vaccine
Total Trials
5
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
5Total
P 1 (5)
Trial Status
Recruiting3
Not Yet Recruiting2
Clinical Trials (5)
Showing 5 of 5 trials
NCT07583654Phase 1Not Yet RecruitingPrimary
Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors
NCT07040943Phase 1Recruiting
Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.
NCT07418229Phase 1Not Yet Recruiting
Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine
NCT07400003Phase 1Recruiting
Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine
NCT07100210Phase 1Recruiting
A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity
Showing all 5 trials